首页> 外文期刊>Journal of Psychiatry and Brain Science >The Prescription Opioids and Depression Pathways Cohort Study ?
【24h】

The Prescription Opioids and Depression Pathways Cohort Study ?

机译:处方阿片类药物和抑郁症途径队列研究?

获取原文
           

摘要

Background: Results from studies using medical record data indicate chronic (90 days) opioid analgesic use (OAU) is associated with new depressive episodes (NDE), worsening depression and risk for depression recurrence. This body of evidence is based on retrospective cohort studies and medical record data. Limitations of existing research are overcome in a new prospective cohort study of the opioid-depression relationship. Methods: Prospective cohort of 1500 adult patients recruited from two health care systems. Eligible subjects started a new period of OAU and have 30 to 90 days of OAU at baseline. Diagnostic assessments for psychiatric disorders, structured measures of pain, pain functioning, opioid use, social support, sleep and impulsivity will be obtained at baseline, 6-month and 12-month follow-up. Baseline participants will be invited to 12 monthly brief assessments of pain-related functioning, depression symptoms and opioid use. Innovation: Robust control for confounding by indication and detailed phenotyping of depression and opioid use disorder. Anticipated results: Chronic OAU will be associated with new onset of a depression phenotype characterized by anhedonia and somatic symptoms. This relationship will be partly, but not completely explained by impaired functioning and low social support. Conclusions: Although the annual number of opioid prescriptions in the United States has decreased, over 190 million patients have OAU each year. If chronic OAU leads to a clinically meaningful affective disorder, independent of pain, then we need to consider depression an important adverse effect of chronic OAU and adjust care for chronic pain accordingly.
机译:背景:使用医疗记录数据的研究结果表明慢性(> 90天)阿片类镇痛使用(OAU)与新的抑郁发作(NDE)相关,恶化抑郁和抑郁复发风险。这一证据基于回顾性队列研究和医疗记录数据。在阿片类药物抑郁症关系的新预期队列研究中克服了现有研究的局限性。方法:来自两名医疗保健系统的1500名成年患者的预期队列。符合条件的受试者开始新的非统组织,并在基线拥有30至90天的OAU。在基线,6个月和12个月的随访中,将获得精神病疾病,疼痛,疼痛,疼痛,阿片类药物,社会支持,睡眠和冲动的结构性障碍,疼痛功能,睡眠和冲动的诊断评估。基线参与者将被邀请12月短暂评估疼痛相关的功能,抑郁症状和阿片类药物使用。创新:通过征兆和抑郁症和阿片类药物的详细表型对混淆的鲁棒控制。预期结果:慢性非统组织将与抑郁症表型的新发作相关,所述抑郁表型以嗜阳症和躯体症状为特征。这种关系将部分,但不能完全解释作用受损和低社会支持。结论:虽然美国的阿片类药物处方数量下降,但每年有超过1.9亿名患者。如果慢性OAU导致临床有意义的情感障碍,无关,那么我们需要考虑抑郁症对慢性OAU的重要不良影响,并相应地调整慢性疼痛的护理。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号